Anemia management in chronic kidney disease: Intravenous iron steps forward

American Journal of Hematology

Volumn 85, Issue 5, 2010, Pages 311-312

  Coyne, Daniel W ^a   Auerbach, Michael ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FERUMOXYTOL; IRON;

ANEMIA; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; IRON THERAPY; NOTE; PRIORITY JOURNAL; QUALITY OF LIFE; STROKE; THROMBOSIS;

ANEMIA, IRON-DEFICIENCY; FERROSOFERRIC OXIDE; HEMATINICS; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; QUALITY OF LIFE;

EID: 77951580026     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21682     Document Type: Note

References (23)

1. Lu M, Suh KR, Lee H-Z, Cohen MH, Rieves D, Pazdur R. FDA review of ferumoxytol (Feraheme) for the treatment of iron deficiency anemia in adults with chronic kidney disease. Am J Hematology 2010.
2. Unger EF, Thompson AM, Blank MJ, Temple R. Erythropoiesis-stimulating agents-time for a reevaluation. N Engl J Med 2010;362:189-192.
3. Coyne DW. Ferumoxytol for treatment of iron deficiency anemia in patients with chronic kidney disease. Exp opinin pharmacother 2009;10:2563-2568.
4. Balakrishnan VS, Rao M, Kausz AT, et al. Physicochemical properties of ferumoxytol, a new intravenous iron preparation. Eur J Clin Invest 2009;39:489-496.
5. AMAG Pharmaceuticals, Inc. Ferumoxytol (Feraheme) Injection. FDA Package Insert, AMAG Pharmaceuticals, Inc.; 2009. http://www.accessdata.fda.gov/ drugsatfda-docs/label/2009/022180lbl.pdf. Accessed on 24 February 2010.
6. Gasche C, Berstad A, Befrits R, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis 2007;13:1545-1553.
7. Provenzano R, Schiller B, Rao M, et al. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol 2009; 4:386-393.
8. Singh A, Patel T, Hertel J, et al. Safety of Ferumoxytol in patients with Anemia and CKD. Am J Kidney Dis 2008; 52; 907-915.
9. Agarwal R, Rizkala AR, Kaskas MO, et al. Iron sucrose causes greater proteinuria than ferric gluconate in non-dialysis chronic kidney disease. Kidney Int 2007;72:638-642. (Pubitemid 47312801)
10. Sanai T, Oochi N, Okada M, et al. Effect of saccharated ferric oxide and iron dextran on the metabolism of phosphorus in rats. J Lab Clin Med 2005;146: 25-29. (Pubitemid 40982016)
11. Schouten BJ, Hunt PJ, Livesey JH, et al. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab 2009;94:2332-2337.
12. Shimizu Y, Tada Y, Yamauchi M, et al. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone 2009;45:814-816.
13. Kalantar-Zadeh K, Regidor DL, Mcallister CJ, et al. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 2005;16:3070-3080. (Pubitemid 44743505)
14. Rodgers GM, Auerbach M, Cella D, et al. High-molecular weight iron dextran: a wolf in sheep's clothing? J Am Soc Nephrol 2008;19:833-834.
15. Rodgers GM, Becker PS, Bennett CL, et al. Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw 2008;6:536-564.
16. Auerbach M, Al Talib K. Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease. Kidney Int 2008;73:528-530. (Pubitemid 351264124)
17. Auerbach M. Holder for INFeD in 1 hour reference. Blood, in press.
18. Kapoian T, O'mara NB, Singh AK, Moran J, Rizkala AR, Geronemus R, Kopelman RC, Dahl NV, Coyne DW. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 2008;19:372-379.
19. Auerbach M, Coyne D, Ballard H. Intravenous iron: from anathema to standard of care. Am J Hematol 2008;83:580-588. (Pubitemid 351874877)
20. Coyne DW. A comprehensive vision for intravenous iron therapy. Am J Kidney Dis 2008;52:S14-20.
21. Spinowitz BS, Kausz AT, Baptista J, et al. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol 2008;19:1599-1605.
22. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-2032.
23. Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:2436-2448.